miR-9a-5p miRNA Inhibitor

CAT.NO	UNIT	PRICE
		$285.00

Specifications

Print Version

Description	microRNAs (miRNAs) are small non-coding RNA sequences important for gene regulation. This miR-9a-5p miRNA inhibitor is designed to bind to miR-9a-5p mature miRNA, inhibiting its effect on the cell. This miRNA inhibitor can be used in experiments to investigate miRNA targets and roles in the cell.
SKU	10011746
Accession Number	MIMAT0000781
Description	This miRNA AAV vector is part of abm’s AAV Expression System and can be packaged into virus using an appropriate packaging mix to over-express your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066300
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Vector
Reporter	GFP
Serotype	N/A
Vector Map	pAAV-miR-OFF
Format	Vector
Insert	Anti-miRNA
QC	Restriction Enzyme Digest and Sequencing
Storage Condition	AAV Vectors are shelf stable for 1 year when stored at -20°C or below. Shipping and short term storage are acceptable at ambient temperature. Avoid repeated freeze-thaw cycles.
Recommended Controls	pAAV-miR-Off-Blank (Cat# Am00700)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	500 ng
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066301
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 1
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 1 (Cat# Am00701)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066302
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 2
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 2 (Cat# Am00702)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066303
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 3
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 3 (Cat# Am00703)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066304
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 4
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 4 (Cat# Am00704)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066305
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 5
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 5 (Cat# Am00705)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066306
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 6
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 6 (Cat# Am00706)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066307
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 7
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 7 (Cat# Am00707)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066308
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 8
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 8 (Cat# Am00708)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066309
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 9
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 9 (Cat# Am00709)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.
Description	This ready-to-use AAV is part of abm’s AAV Expression System and can be used directly to knockdown your miRNA of interest in a wide range of host cells or animal models.
SKU	Amr3066310
Features	GFP Reporter
Accession Number	MIMAT0000781
miRNA ID	MIMAT0000781
miRNA Name	rno-miR-9a-5p
Gene Name	rno-miR-9a-5p
Species	Rat
System	AAV Virus
Reporter	GFP
Serotype	AAV Serotype 10
Vector Map	pAAV-miR-OFF
Titer	>1 x 10⁹ GC/ml
Format	Virus
Insert	Anti-miRNA
QC	qPCR Based Titer Determination and Transduction Efficiency Test
Storage Condition	AAV viruses are shipped with dry ice. For long term storage, it is recommended to store the viruses at -80°C in small aliquots to avoid repeated freeze-thaw cycles.
Recommended Controls	AAV-miR-Off-Blank Serotype 10 (Cat# Am00710)
Mammalian Selection Marker	Puromycin
Bacterial Selection	kanamycin
Unit quantity	5 x 200 μl
Disclaimer	1) Disclaimer for Transcript Variants: The provided accession number refers to the transcript (mRNA) sequence for this product. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. All sales are final. 2) Disclaimer for Gene Sequence: The provided accession number refers to the transcript (mRNA) sequence for this product. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 3) Disclaimer for Intended Use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 4) Disclaimer for Extra Nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct. 5) abm guarantees that at least 1 out of the 3 sgRNA constructs purchased in a set designed to be used with Cas9 Nuclease will result in gene knock-out due to frameshift mutations in over 50% of cells, after successful infection and drug selection. This guarantee applies to sgRNAs designed to target human, mouse or rat genes only. If knock-out is not achieved in extremely rare cases, a one-time replacement of another set of 3 targets with alternative sgRNA sequences will be provided. To qualify for this replacement, customers must examine knock-out efficiency by Surveyor assay. Before sending your inquiry, please make sure you have optimized your experiments as far as possible. This includes (where applicable) increasing and optimizing your MOI, increasing the duration of infection (up to 72 h), and carrying out clone screening before assaying for knock-out. Please also provide data to show that a reporter virus was used to optimize the MOI for your target cell line. Customers must provide adequate data to show >80% infection efficiency with a positive control, plus additional qPCR data to evaluate the level of mRNA expression. For vector transfection, please evaluate the vector transfection efficiency by detecting Cas9 or puromycin expression for the 'All-in-One' vectors using qPCR, or neomycin for constructs containing only the sgRNA. In addition, please provide Surveyor Assay or Sanger Sequencing data on at least 20 isolated clones. abm limits its obligation and liability for the success of this technology to providing one replacement of any sgRNA lentivector product only. The replacement set will not be covered by the same guarantee. If these constructs are also considered to be ineffective then the gene is most likely not susceptible to sgRNA knock-out.

Documents

Supporting Protocol

Other

FAQs

What is the Sanger miRBase Sequence Database?

miRBase is a sequence database that has been established by the Sanger Institute. Each entry in the microRNA Registry represents a predicted hairpin portion of a microRNA transcript (termed mir in the database), with information on the location and sequence of the mature microRNA sequence (termed miR). The database provides microRNA gene hunters with unique names for novel microRNA genes prior to publication of results and a searchable database of published microRNA.

	When was the latest update of your array sequences?
The content of our arrays has been updated to miRBase Release 16.0.

	Do you sell any products that allow detection of microRNAs using in-situ methods
We currently don't have in-situ miRNA detection methods.

	Is there any product literature?
Cheng, A.M., Byrom, M.W., Shelton, J., et al. (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33, 1290–1297

How do I detect the reduced level of the miRNA after inhibition?

Target miRNA is not degraded, but it is silenced by the antisense strand expressed by the inhibitor construct, which will effectively bind and sequester it. Using qPCR to detect changes in downstream target gene expression is therefore recommended. Another method is to use a GFP/luciferase 3' UTR reporter that contains a known miRNA target site to detect changes in reporter expression (http://www.abmgood.com/3%27UTR-Reporter-Cell-Line.html).

	Can RISC-combined-fragment bind/inhibit RISC-combined-(target)miRNA?
The exact inhibition mechanism is unknown. It is experimentally demonstrated that the expressed anti-sense miRNA will prevent the target miRNA from binding to its gene 3'UTR target.

How does inhibitory miRNA lentivirus (LentimiRa-Off) work?

Inhibitory miRNA lentivirus works by expressing anti-sense microRNAs (in siRNA form). There are many references for anti-sense miRNA knockdown properties. The way the inhibitor is processed is more similar to shRNA than miRNA processing, so the flanking native miRNA sequences are not required. The inhibitor (antisense to the mature sequence) will be processed in the shRNA pathway and will knockdown the miRNA as an shRNA would normally knockdown mRNA of its target gene. Please check the following Cheng, A.M., Byrom, M.W., Shelton, J., et al. (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33, 1290–1297.

	what is the difference between miRNA and the miRNA with the asterisk symbol?
miRNA and miRNA* are the two different double-stranded products from dicer processing of the same precursor miRNA. the miRNA without the asterisk represent the predominant product and the one with the asterisk represent the portion from the opposite arm of the precursor. More information on the names can be found in the link below: http://www.mirbase.org/help/nomenclature.shtml

	Do you have any mutant constructs available for the 3'UTR miRNA reporter vectors for miRNA-mRNA interaction validation?
We do not have any mutant constructs in our inventory, all the listed constructs are wild type. We can offer mutant constructs as a custom service. The exact sequence to be mutated must be supplied by the end-user in each case. Please contact [email protected] with any specific requests.

	Do I need to use an internal control primer for quantitative detection of miRNAs (the same as housekeeping primers which we use in qPCR for mRNAs detection)?
For human miRNA plates, the controls are as follows: 1) SNORD44, cat MPH00003 2) SNORD47, cat MPH00004 3) SNORD48, cat MPH00005 4) U6-2, cat MPH00001

	After cell transduction with the vector,should I dedetect pri-miRs or mature miRs?
The mature miRs could be detected after transduction/infection.

	What promoter is the miRNA under?
The miRNA is being expressed through a CMV promoter.

What is the genetic structure of the miRNA off insert?

The off-insert is expressed by the H1 promoter and will form a stem loop structure like immature shRNA that is complementary to the targeted miRNA. We take the antisense (the inhibitor) to the mature miRNA sequence and form a hairpin structure with the mature miRNA sequence (has several mutations in it to render it inactive) after transcription. The inhibitor gets processed in the same pathway as regular miRNA precursors and the resulting antisense inhibitor actively knocks down mature miRNA. The structure of the inhibitory insert goes like this: mature miRNA sequence (with mutations) - Hairpin loop - Antisense miRNA sequence (inhibitor) - TTTTTT termination sequence.

	What sequencing primers can I use?
The reverse sequencing primer is 5'-GGAACATACGTCATTATTGACGTC-3'. A forward primer is 5'-GTGTCACTAGGCGGGAACAC-3'.

	How does miRNA inhibitor adenovirus work?
The miRNA inhibitor is in the form of a short hairpin which is complementary to the mature miRNA sequence that it targets. Its expression is under the control of the H1 promoter in an Adenovirus vector. The packaged adenovirus can be used to transfect your target cells and deliver the miRNA inhibitor into the cells and knockdown its target mature miRNA.

	Can I quantify mature miRNA in total RNA using your cDNA synthesis and kit and qPCR master mix?
Yes, that is what it is designed for.

In the manual, the vector map is shown with mature miRNA flanked by miR-30 (mir BB part of the vector map) to form the premature miRNA. What happens to the miR-30?

There will be no final mir-30 expression. The miR-30 (also known as mir BB in the map) remains in the vector backbone and is used for miRNA processing. The final miRNA expressed is the mature target miRNA only. Reference: Cullen et. al. 2003. Sequence requirements for micro RNA processing and function in human cells. RNA. 9(1): 112–123. Guo et al. 2009. Construction of an Artificial MicroRNA Expression Vector for Simultaneous Inhibition of Multiple Genes in Mammalian Cells. IJMS.

	Which genes are targeted by a specific miRNA?
You can search for predicted and validated miRNA target genes at http://mirbase.org/. Just type in your miRNA name (eg. hsa-mir-145) or accession number in the search bar and look for the targeted genes.

	Are these vectors supplied lyophilised or in solution?
Our miRNA lentivectors are provided as 500ng DNA in 10ul storage buffer solution composed of 10mM Tris-HCI, 1mM EDTA, pH 8.0.

	What promoter drives the inhibitory miRNA?
H1 Promoter

	Does the profiling (qPCR) require a specific instrument or it can be done by every real time PCR instrument?
We have a range of miRNA qPCR mastermixes available in optimized formulations for all qPCR machines, please see our web page http://www.abmgood.com/miRNA-qPCR-Mastermixes-microRNA-qPCR.html

	is there a reporter gene for the miRNA adenovirus?
All of the miRNA adenoviruses have a GFP reporter gene.

	Is there a reporter gene for the miRNA inhibitory adenovirus?
All of the miRNA inhibitory adenoviruses have a GFP reporter gene.

	What insertion/restriction sites are used to clone the inhibitory miRNA sequence into the vector?
The sites used for all miRNA inhibitor constructs are XbaI/XhoI

	pLenti-III-miR-Off system or LentimiRa system uses blank vector for control, but I usually use scrambled control for si-RNA experiments. Is it supported to use blank control not scrambled for miRNA experiments?
Both scrambled and blank controls are effective negative controls. However, there are debates over off-target effects when using scrambled sequences. By using a blank vector as negative control, the off-target effect can be eliminated. If your experiment requires a scrambled control over a blank control, we can custom make that for you as well upon request.

	Why are miRNA mimics on your site offered at 2 x 2.5nmol, but miRNA inhibitors at 2 x 5.0nmol?
This is because our mimics now are double-stranded while the inhibitors are single-stranded. The amount of materials are quantified in OD and both mimics/inhibitors are synthesized to yield the same OD. Therefore, the number of moles of mimics is half of that of the inhibitors.

References

Liang, Y., Song, X., Li, Y., Su, P., Han, D., Ma, T., … Yang, Q. "circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer" Oncogene 38(42):6850–6866 (2019). DOI: 10.1038/s41388-019-0926-z.
Verma, M., Asakura, Y., & Asakura, A. "Inhibition of microRNA‐92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy–related phenotype in mdx mice" Muscle & Nerve 59(5):594–602 (2019). DOI: 10.1002/mus.26433.
Wu., Chien-Wei., . "Downregulation of MiR-144 by Triptolide Enhanced p85α−PTEN Complex Formation Causing S Phase Arrest of Human Nasopharyngeal Carcinoma Cells" European Journal of Pharmacology 855:137-148 (2019). DOI: 10.1016/j.ejphar.2019.04.052..
Wu, M.-J., Chen, Y.-S., Kim, M. R., Chang, C.-C., Gampala, S., Zhang, Y., … Chang, C.-J. "Epithelial-Mesenchymal Transition Directs Stem Cell Polarity via Regulation of Mitofusin" Cell Metabolism 29(4):993–1002.e6 (2019). DOI: 10.1016/j.cmet.2018.11.004.
Xiang, X., Zhou, Y., Sun, H., Tan, S., Lu, Z., Huang, L., & Wang, W. "Ivabradine abrogates TNF-α-induced degradation of articular cartilage matrix" International Immunopharmacology 66:347–353 (2019). DOI: 10.1016/j.intimp.2018.11.035.
Zhou, Y., Lei, J., Xie, Q., Wu, L., Jin, S., Guo, B., ... & Zhang, J. "Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5" Science Advances 5(11):eaax0629 (2019).
Zhu, R., Xue, X., Shen, M., Tsai, Y., Keng, P. C., Chen, Y., … Chen, Y. "NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer" Experimental Cell Research 374(1):181–188 (2019). DOI: 10.1016/j.yexcr.2018.11.022.